Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Investors Balk At AMAG-Allos Proposed Marriage

This article was originally published in The Pink Sheet Daily

Executive Summary

An all-stock merger worth up to $686 million would strengthen the companies' balance sheet, commercial presence, and cost structures, but Wall Street is concerned about logistics and execution.

You may also be interested in...



Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos

AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.

Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos

AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.

Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging

A wave of biotechs is making the milestone move from drug developer to drug marketer, but investors are less interested than ever in sticking around for the potential long-term rewards.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel